

Tom Mikkelsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10716306/publications.pdf>

Version: 2024-02-01

98
papers

26,195
citations

47006

47
h-index

38395

95
g-index

103
all docs

103
docs citations

103
times ranked

26524
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics for precision medicine in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 217-231.	2.9	22
2	Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors. <i>Neuro-Oncology</i> , 2022, 24, 1126-1139.	1.2	9
3	A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. <i>Neuro-Oncology</i> , 2021, 23, 468-477.	1.2	28
4	A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. <i>Neurosurgery</i> , 2021, 88, 246-251.	1.1	16
5	A serum-based DNA methylation assay provides accurate detection of glioma. <i>Neuro-Oncology</i> , 2021, 23, 1494-1508.	1.2	53
6	Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 593-613.	3.0	21
7	Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 353-361.	2.9	16
8	Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery. <i>Oncotarget</i> , 2020, 11, 443-451.	1.8	16
9	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
10	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	1.9	56
11	Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. <i>Nature Genetics</i> , 2018, 50, 708-717.	21.4	212
12	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	1.2	24
13	A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. <i>Cell Reports</i> , 2018, 23, 637-651.	6.4	137
14	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 259-267.	1.2	41
15	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 249-258.	1.2	78
16	RTHP-06. RANDOMIZED PROSPECTIVE TRIAL OF STEREOTACTIC RADIOSURGERY VERSUS CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMA AFTER SECOND-LINE CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi226-vi226.	1.2	3
17	ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi6-vi7.	1.2	1
18	RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB. <i>Neuro-Oncology</i> , 2018, 20, vi241-vi241.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	1.2	135
20	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
21	A parametric model of the brain vascular system for estimation of the arterial input function (AIF) at the tissue level. <i>NMR in Biomedicine</i> , 2017, 30, e3695.	2.8	15
22	DCE-MRI prediction of survival time for patients with glioblastoma multiforme: using an adaptive neuro-fuzzy-based model and nested model selection technique. <i>NMR in Biomedicine</i> , 2017, 30, e3739.	2.8	16
23	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	1.6	110
24	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	2.3	108
25	Reproducibility and relative stability in magnetic resonance imaging indices of tumor vascular physiology over a period of 24 h in a rat 9L gliosarcoma model. <i>Magnetic Resonance Imaging</i> , 2017, 44, 131-139.	1.8	7
26	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	16.8	1,282
27	NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 193-199.	2.9	55
28	Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research. <i>Comparative Medicine</i> , 2017, 67, 300-314.	1.0	18
29	Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. <i>Oncotarget</i> , 2016, 7, 56456-56470.	1.8	75
30	ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL. <i>Neuro-Oncology</i> , 2016, 18, vi18-vi18.	1.2	1
31	CBIO-10. REVERSIBILITY OF GLIOMA STEM CELLS' SPHERE FORMATION EXPLAINS THEIR IN VITRO BEHAVIOR AND IN VIVO TUMORIGENESIS POTENTIAL. <i>Neuro-Oncology</i> , 2016, 18, vi37-vi37.	1.2	0
32	TMOD-36. GENE EXPRESSION ANALYSIS OF SHORT AND LONG SURVIVAL GROUPS OF GLIOBLASTOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAPTS. <i>Neuro-Oncology</i> , 2016, 18, vi214-vi214.	1.2	0
33	Presenting signs and symptoms in brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 19-26.	1.8	24
34	Predictors of Venous Thromboembolism in Patients with Glioblastoma. <i>Pathology and Oncology Research</i> , 2016, 22, 311-316.	1.9	10
35	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.4	158
36	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563.	28.9	1,695

#	ARTICLE	IF	CITATIONS
37	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
38	CXCR4 increases <i>in-vivo</i> glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. <i>Oncotarget</i> , 2016, 7, 83701-83719.	1.8	75
39	Direct contact with perivascular tumor cells enhances integrin $\alpha 5 \beta 1$ signaling and migration of endothelial cells. <i>Oncotarget</i> , 2016, 7, 43852-43867.	1.8	28
40	Peritumoral tissue compression is predictive of exudate flux in a rat model of cerebral tumor: an MRI study in an embedded tumor. <i>NMR in Biomedicine</i> , 2015, 28, 1557-1569.	2.8	21
41	MRI-Tracked Tumor Vascular Changes in the Hours after Single-Fraction Irradiation. <i>Radiation Research</i> , 2015, 183, 713.	1.5	33
42	Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. <i>Genome Research</i> , 2015, 25, 316-327.	5.5	343
43	Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. <i>Investigational New Drugs</i> , 2015, 33, 247-253.	2.6	45
44	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
45	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582
46	High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 948-952.	2.8	30
47	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015, 17, 708-717.	1.2	191
48	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1386-1392.	1.2	50
49	Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 125, 123-131.	2.9	8
50	Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with ≥ 3 newly diagnosed brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 124, 485-491.	2.9	23
51	Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. <i>Neuro-Oncology</i> , 2015, 17, 440-447.	1.2	102
52	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28
53	RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop. <i>Oncotarget</i> , 2015, 6, 22680-22697.	1.8	29
54	Related to testes-specific, vespid and pathogenesis protein-1 is regulated by methylation in glioblastoma. <i>Oncology Letters</i> , 2014, 7, 1209-1212.	1.8	9

#	ARTICLE	IF	CITATIONS
55	The Cyclin-like Protein Spy1 Regulates Growth and Division Characteristics of the CD133+ Population in Human Glioma. <i>Cancer Cell</i> , 2014, 25, 64-76.	16.8	35
56	Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy. <i>Neoplasia</i> , 2014, 16, 543-561.	5.3	131
57	Outcome Prediction in Patients with Glioblastoma by Using Imaging, Clinical, and Genomic Biomarkers: Focus on the Nonenhancing Component of the Tumor. <i>Radiology</i> , 2014, 272, 484-493.	7.3	196
58	SCA 17 phenotype with intermediate triplet repeat number. <i>Journal of the Neurological Sciences</i> , 2014, 345, 269-270.	0.6	9
59	Sox2 Promotes Malignancy in Glioblastoma by Regulating Plasticity and Astrocytic Differentiation. <i>Neoplasia</i> , 2014, 16, 193-206.e25.	5.3	132
60	Role of MRI in Primary Brain Tumor Evaluation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1561-1568.	4.9	20
61	Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. <i>Journal of Neuro-Oncology</i> , 2013, 112, 413-420.	2.9	31
62	The integrated landscape of driver genomic alterations in glioblastoma. <i>Nature Genetics</i> , 2013, 45, 1141-1149.	21.4	524
63	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	28.9	3,979
64	Double Minute Chromosomes in Glioblastoma Multiforme Are Revealed by Precise Reconstruction of Oncogenic Amplicons. <i>Cancer Research</i> , 2013, 73, 6036-6045.	0.9	94
65	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. <i>Neuro-Oncology</i> , 2013, 15, 490-496.	1.2	79
66	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3212-3218.	1.6	489
67	A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 900-908.	7.0	112
68	Phase I Study of GRN1005 in Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 1567-1576.	7.0	143
69	Cilengitide-Induced Temporal Variations in Transvascular Transfer Parameters of Tumor Vasculature in a Rat Glioma Model: Identifying Potential MRI Biomarkers of Acute Effects. <i>PLoS ONE</i> , 2013, 8, e84493.	2.5	14
70	Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3041-3046.	7.1	459
71	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
72	Transforming Fusions of <i>FGFR</i> and <i>TACC</i> Genes in Human Glioblastoma. <i>Science</i> , 2012, 337, 1231-1235.	12.6	716

#	ARTICLE	IF	CITATIONS
73	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. <i>Journal of Neuro-Oncology</i> , 2012, 108, 491-498.	2.9	149
74	DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e35857.	2.5	27
75	Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 660-668.	1.2	94
76	Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011, 13, 143-151.	1.2	69
77	Recurrent high-grade glioma: a diagnostic and therapeutic challenge. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 509-518.	2.8	20
78	The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 97-102.	2.9	126
79	The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 17-32.	2.9	277
80	The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 33-43.	2.9	361
81	The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. <i>Journal of Neuro-Oncology</i> , 2010, 96, 45-68.	2.9	446
82	Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study. <i>Oncologist</i> , 2010, 15, 1329-1334.	3.7	98
83	Reply to W. Wick et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e190-e192.	1.6	9
84	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972.	1.6	3,222
85	Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4733-4740.	1.6	2,219
86	Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule dependency. <i>International Journal of Cancer</i> , 2009, 124, 2719-2727.	5.1	120
87	Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. <i>Investigational New Drugs</i> , 2007, 25, 259-263.	2.6	31
88	Studying the heterogeneity of brain tumors using medium throughput LOH analysis. <i>Cytometry</i> , 2002, 47, 52-55.	1.8	2
89	Adults with newly diagnosed high-grade gliomas. <i>Current Treatment Options in Oncology</i> , 2001, 2, 507-515.	3.0	20
90	Cathepsin B and glioma invasion. <i>International Journal of Developmental Neuroscience</i> , 1999, 17, 483-494.	1.6	97

#	ARTICLE	IF	CITATIONS
91	The role of protein kinase C β in U87 glioma invasion. International Journal of Developmental Neuroscience, 1999, 17, 447-461.	1.6	33
92	Brain tumor segmentation and characterization by pattern analysis of multispectral NMR images. , 1998, 11, 201-208.		24
93	Feature space analysis of MRI. Magnetic Resonance in Medicine, 1998, 40, 443-453.	3.0	16
94	Cytostatic Agents in the Management of Malignant Gliomas. Cancer Control, 1998, 5, 150-162.	1.8	16
95	Inhibitory effects of CAI in glioblastoma growth and invasion. Journal of Neuro-Oncology, 1997, 32, 93-101.	2.9	35
96	Cerebral tumor volume calculations using planimetric and eigenimage analysis. Medical Physics, 1996, 23, 2035-2042.	3.0	40
97	Genetics of Astrocytic Tumor Progression. , 1993, 3, 69-94.		3
98	Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 1992, 355, 846-847.	27.8	628